Chimerix Gets FDA OK to Test Experimental Drug for Ebola

A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration. Chimerix said Thursday that it has received FDA clearance to proceed with a trial examining the safety and effectiveness of its brincidofovir tablets in patients who have the virus. The company said in a statement that the drug is available for immediate use in testing. With FDA's permission, the Durham, N.C., drugmaker previously made the drug available to the first Ebola patient diagnosed in the U.S., who died in Dallas last week. The FDA does not publicly confirm when it has granted companies permission to begin testing. The agency has not approved any drugs or vaccines to treat Ebola.